Clinical Trial Update: Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing safety and immunogenicity of HEPLISAV-B vaccine to Engerix-B in chronic kidney disease patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• HEPLISAV-B (hepatitis B vaccine, adjuvanted)

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-12-16